Cancer progression and substance P

Histology and Histopathology

Volumn 29, Issue 7, 2014, Pages 881-890

  Coveñas, Rafael ^a   Muñoz, Miguel ^b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

Angiogenesis; Aprepitant; Metastasis; NK 1 receptor; NK 1 receptor antagonist; Tumor

Indexed keywords

NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; SUBSTANCE P;

ANIMAL; DISEASE COURSE; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR INVASION;

ANIMALS; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEUROKININ-1 RECEPTOR ANTAGONISTS; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 84902987346     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Alfieri A.B. and Cubeddu L.X. (2000). Role of NK1 receptors on cisplatin-induced nephrotoxicity in the rat. Naunyn. Schmiebergs. Arch. Pharmacol. 361, 334-338.
2. Alfieri A.B. and Cubeddu L.X. (2004). Efectos de los antagonistas de los receptores NK1 y de la dexametasona sobre la inflamación neurogénica inducida por ciclofosfamida y por radiación X, en la rata. AVFT 23, 61-66.
3. Bigioni M., Benzo A., Irrissuto C., Maggi C.A. and Goso C. (2005). Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs 16, 1083-1089.
4. Brener S., González-Moles M.A., Tostes D., Esteban F., Gil-Montoya J.A., Ruiz-Avila I., Bravo M. and Muñoz M. (2009). A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. Anticancer Res. 29, 2323-2329.
5. Cook G.A., Elliott D., Metwali A., Blu A.M., Sandor M., Lynch R. and Weinstock J.V. (1994). Molecular evidence that granuloma T lymphocytes in murine Schistosomiasis mansoni express an authentic SP (NK1) receptor. J. Immunol. 152, 1830-1835.
6. DeFea K.A., Vaughn Z.D., O'Bryan E.M., Nishijima D., Dery O. and Bunnett N.W. (2000). The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestindependent scaffolding complex. Proc. Natl. Acad. Sci. USA 97, 11086-11091.
7. Esteban F., Muñoz M., González-Moles M.A. and Rosso M. (2006). A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metast. Rev. 25, 137-145.
8. Esteban F., Gonzalez-Moles M.A., Castro D., Martín-Jaén M., del M., Redondo M., Ruiz-Avila I. and Muñoz M. (2009). Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology 54, 258-260.
9. Exadaktylos A.K., Buggy D.J., Moriarty D.C., Mascha E. and Sessler D.I. (2006). Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 105, 660-664.
10. Fackler O.T. and Grosse R. (2008). Cell motility through plasma membrane blebbing. J. Cell Biol. 181, 879-884.
11. Feng F., Yang J., Tong L., Yuan S., Tian Y., Hong L., Wang W. and Zhang H. (2011). Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells. Cell Biol. Int. 35, 623-629.
12. Friess H., Zhu Z., Liard V., Shi X., Shrikhande S.V., Wang L., Lieb K., Korc M., Palma C., Zimmermann A., Reubi J.C. and Buchler M.W. (2003). Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab. Invest. 83, 731-742.
13. Gillespie E., Leeman S.E., Watts L.A., Coukos J.A., O'Brien M.J., Cerda S.R., Farraye F.A., Stucchi A.F. and Becker J.M. (2011). Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer. Proc. Natl. Acad. Sci. USA 108, 17420-17425.
14. Gitter B.D., Regoli D., Howbert J.J., Glasebrook A.L. and Waters D.C. (1994). Interleukin-6 secretion from human astrocytoma cells induced by substance P. J. Neuroimmunol. 51, 101-108.
15. González-Moles M.A., Mosqueda-Taylor A., Esteban F., Gil-Montoya J.A., Díaz-Franco M.A., Delgado M. and Muñoz M. (2008). Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours. Oral Oncol. 44, 1127-1133.
16. Guha S., Eibl G., Kisfalvi K., Fan R.S., Burdick M., Reber H., Hines O.J., Strieter R. and Rozengurt E. (2005). Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,DTrp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res. 65, 2738-2745.
17. Hargreaves R., Ferreira J.C., Hughes D., Brands J., Hale J., Mattson B. and Mills S. (2011). Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann. NY Acad. Sci. 1222, 40-48.
18. Hennig I.M., Laissue J.A., Horisberger U. and Reubi J.C. (1995). Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int. J. Cancer 61, 786-792.
19. Johnson C.L. and Johnson C.G. (1993). Substance P regulation of glutamate and cystine transport in human astrocytoma cells. Receptors Channels 1, 53-59.
20. Keranen U., Jarvinen H., Karkkaine P., Kiviluoto T., Kivilaakso E. and Soinila S. (1996a). Substance P - an underlying factor for pouchitis? Prospective study of substance P and VIP-immunoreactive innervation and mast cells. Dig. Dis. Sci. 41, 1665-1671.
21. Keranen U., Jarvinen H., Kiviluoto T., Kivilaakso E. and Soinila S. (1996b). Substance P and VIP-immunoreactive innervation in normal and inflamed pouches after restorative proctocolectomy for ulcerative colitis. Dig. Dis. Sci. 41, 1658-1664.
22. Khare V.K., Albino A.P. and Reed J.A. (1998). The neuropeptide/mast cel l secretagogue substance P is expressed in cutaneous melanocytic lesions. J. Cutan. Pathol. 25, 2-10.
23. Kitchens C.A., McDonald P.R., Pollack I.F., Wipf P. and Lazo J.S. (2009). Synergy between microtubule destabilizing agents and neurokini 1 receptor antagonists identified by an siRNA synthetic lethal screen. FASEB J. 23, 756.13.
24. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Halle J.J., Mills S.G., MacCoss M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Carlsson E.J., Hargreaves R.J. and Rupniak N.M. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640-1645.
25. Lang K., Drell T.L., Lindecke A., Niggemann B., Kaltschmidt C., Zaenker K.S. and Entschladen F. (2004). Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int. J. Cancer 112, 231-238.
26. Lewis K.M., Harford-Wright E., Vink R., Nimmo A.J. and Ghabriel M.N. (2013). Walker 256 tumour cel ls increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasat ion and brain invasion. Cl in. Exp. Metastasis 30, 1-12.
27. Li X., Ma G., Ma Q., Li W., Liu J., Han L., Duan W., Xu Q., Liu H., Wang Z., Sun Q., Wang F. and Wu E. (2013). Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Mol. Cancer Res. 11, 294-302.
28. Luo W., Sharif T.R. and Sharif M. (1996). Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res. 56, 4983-4991.
29. Manske J.M. and Hanson S.E. (2005). Substance P-mediated immunomodulat ion of tumor growth in a murine model. Neuroimmunomodulation 12, 201-210
30. Medrano S., Gruenstein E. and Dimlich R.V. (1994). Substance P receptors on human astrocytoma cells are linked to glycogen breakdown. Neurosci. Lett. 167, 14-18.
31. Meshki J., Douglas S.D., Lai J.P., Schwartz L., Kilpatrick L.E. and Tuluc F. (2009). Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinasedependent mechanism. J. Biol. Chem. 284, 9280-9289.
32. Morgan G., Ward R. and Warton M. (2004). The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin. Oncol. 16, 549-560.
33. Muñoz M. and Coveñas R. (2013a). Involvement of substance P and the NK-1 receptor in cancer progression. Peptides 48, 1-9.
34. Muñoz M. and Coveñas R. (2013b). Safety of neurokinin-1 receptor antagonists. Expert Opin. Drug Saf. 12, 673-685.
35. Muñoz M. and Rosso M. (2010). The NK-1 receptor antagonist aprepitant as a broad-spectrum antitumor drug. Invest. New Drugs 28, 187-193.
36. Muñoz M., Rosso M., Pérez A., Coveñas R., Rosso R., Zamarriego C., Soult J.A. and Montero I. (2005a). Antitumoural action of the neurokinin 1 receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest. Ophthalmol. Vis. Sci. 46, 2567-2570.
37. Muñoz M., Rosso M., Pérez A., Coveñas R., Zamarriego C. and Piruat J.I. (2005b). The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 39, 427-432.
38. Muñoz M., Rosso M., Coveñas R., Montero I., González-Moles M.A. and Robles M.J. (2007). Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist L-732,138. Invest. Ophthalmol. Vis. Sci. 48, 2775-2781.
39. Muñoz M., Rosso M., Aguilar F.J., González-Moles M.A., Redondo M. and Esteban F. (2008). NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest. New Drugs 26, 111-118.
40. Muñoz M., Rosso M. and Coveñas R. (2010a). A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr. Med. Chem. 17, 504-516.
41. Muñoz M., Rosso M., Casinel lo F. and Coveñas R. (2010b). Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. Breast Cancer Res. Treat. 122, 601-603.
42. Muñoz M., Rosso M., Robles-Frías M.J., Salinas-Martín M.V. and Coveñas R. (2010c). The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab. Invest. 90, 1259-1269.
43. Muñoz M., Bernabeu-Wittel J. and Coveñas R. (2011a). NK-1 as a melanoma target. Expert Opin. Ther. Targets 15, 889-897.
44. Muñoz M., Rosso M. and Coveñas R. (2011b). The NK-1 receptor: a new target in cancer therapy. Curr. Drug Targets 12, 909-921.
45. Muñoz M., González-Ortega A. and Coveñas R. (2012a). The Nk-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. Invest. New Drugs 30, 529-540.
46. Muñoz M., González-Ortega A., Rosso M., Robles-Frías M.J., Carranza A., Salinas-Martín M.V. and Coveñas R. (2012b). The substance P/Neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides 38, 318-325.
47. Muñoz M., Martínez-Armesto J. and Coveñas R. (2012c). NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011. Expert Opin. Ther. Patents 22, 735-746.
48. Muñoz M., Berger M., Rosso M., González-Ortega A., Carranza A. and Coveñas R. (2014). Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. Int. J. Oncol. 44, 137-146.
49. Nakajima Y., Tsuchida K., Negishi M., Ito S. and Nakanishi S. (1992). Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cAMP cascades in transfected Chinese hamster ovary cells. J. Biol. Chem. 267, 2437-2442.
50. Nowicki M. and Miskowiak B. (2002). Comparison of the cel l immunophenotype of metastatic and primary foci in stage IV-S neuroblastoma. Folia Histochem. Cytobiol. 40, 297-303.
51. Nowicki M., Miskowiak B. and Ostalska-Nowicka D. (2003). Detection of substance P and its mRNA in human blast cells in childhood lymphoblastic leukaemia using immunocytochemistry and in situ hybridisation. Folia Histochem. Cytobiol. 41, 33-36.
52. O'Connor T.M., O'Connell J., O'Brien D.I., Goode T., Bredin C.P. and Shanahan F. (2004). The role of substance P in inflammatory disease. J. Cell Physiol. 201, 167-180.
53. Olver I., Shelukar S. and Thompson K.C. (2007). Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int.
54. Palma C., Bigioni M., Irrissuto C., Nardelli F., Maggi C.A. and Manzini S. (2000). Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br. J. Cancer 82, 480-487.
55. Patel H.J., Ramkissoon S.H., Patel P.S. and Rameshwar P. (2005). Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc. Natl. Acad. Sci. USA 102, 17436-17441.
56. Prasad S., Mathur A., Jaggi M., Singh A.T. and Mukherjee R. (2007). Substance P analogs containing alpha, alpha-dialkylated amino acids with potent anticancer activity. J. Pept. Sci. 13, 544-548.
57. Rodríguez PL, Jiang S, Fu Y, Avraham S. and Avraham HK. (2013). The proinflammatory peptide substance P promotes blood-brain barrier breaching by breast cancer cells through changes in microvascular endothelial cell tight junctions. Int. J. Cancer (in press).
58. Rosso M., Robles-Frías M.J., Coveñas R., Salinas-Martín M.V. and Muñoz M. (2008). The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumor Biol. 29, 245-254.
59. Rost K., Fleischer F. and Nieber K. (2006). Neurokinin-1 receptor antagonists: between hope and disappointment. Med. Monatsschr. Pharm. 29, 200-205.
60. Ruhlmann C.H. and Herrstedt J. (2011). Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Expt. Opin. Drug Saf. 10, 449-462.
61. Saito H., Yoshizawa H., Yoshimori K., Katakami N., Katsumata N., Kawahara M. and Eguchi K. (2013). Efficacy and safety of singledose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-bind, placebo-controlled phase 3 trial. Ann. Oncol. 24, 1067-1073.
62. Sánchez R.I., Wang R.W., Newton D.J., Bakhtiar R., Lu P., Chiu S.H., Evans D.C. and Huskey S.E. (2004). Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab. Dispos. 32, 1287-1292.
63. Seckl M.J., Higgins T., Widmer F. and Rozengurt E. (1997). [D-Arg1,D Trp5,7,9,Leu11]substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res. 57, 51-54.
64. Sendo T., Itoh Y., Goromaru T., Hirakawa T., Ishida M., Nakano H. and Oishi R. (2004). Role of substance P in hypersensitivity reactions induced by paclitaxel, an anticancer agent. Peptides 25, 1205-1208.
65. Singh D., Joshi D.D., Hameed M., Qian J., Gascón P., Maloof P.B., Mosenthal A. and Rameshwar P. (2000). Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc. Natl. Acad. Sci. USA 97, 388-393.
66. Spiegel D. and Giese-Davis J. (2003). Depression and cancer: mechanisms and disease progression. Biol. Psychiatry 54, 269-282.
67. Sporn M.B. (1996). The war on cancer. Lancet 347, 1377-1381.
68. Stiff P.J., Fox-Geiman M.P., Kiley K., Rychlik K., Parthasarathy M., Fletcher-Gonzalez D., Porter N., Go A., Smith S.E. and Rodriguez T.E. (2013). Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic. Biol. Blood Marrow Transplant. 19, 49-55.
69. Takeda Y., Blount P., Sachais B.S., Hershey A.D., Raddatz R. and Krause J.E. (1992). Ligand binding kinetics of substance P and neurokinin A receptors stably expressed in Chinese hamster ovary cells and evidence for differential stimulation of inositol 1, 4, 5-triphosphate and cyclic AMP second messenger responses. J. Neurochem. 59, 740-745.
70. Tarkkanen A., Tervo T., Tervo K., Eränko L., Eränko O. and Cuello A.C. (1983). Substance P immunoreactivity in normal human retina and in retinoblastoma. Opthalmic. Res. 15, 300-306.
71. Tung W.L. and Lee C.M. (1991). Effects of tachykinins on [3H]taurine release from human astrocytoma cells (U-373 MG). Brain Res. 549, 171-173.
72. Walsh D.T., Weg V.B., Williams T.J. and Nourshargh S. (1995). Substance P induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators. Br. J. Pharmacol. 114, 1343-1350.
73. Warburg O. (1956). On the origin of cancer cells. Science 123, 309-314.
74. Ziche M., Morbidelli L., Pacini M., Gepetti P., Alessandri G. and Maggi C.A. (1990). Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc. Res. 40, 264-278.